A Phase 1b Study to Evaluate the Safety Tolerability and Preliminary Efficacy of ATP150/ATP152 VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma

Brief description of study

This study is designed for patients with resected KRAS G12D/G12V mutated pancreatic cancer.This is an open-label, phase 1b study comprising of two parts (safety and immunogenicity part andrandomized efficacy part) to evaluate the safety, tolerability, preliminary efficacy, and immunogenicityof a heterologous prime-boost vaccine (protein and viral vector) strategy, in which approximately 85 patients with KRAS G12D/G12V mutated pancreatic cancer will be enrolled in the following treatment parts of the study:

Part A (Safety and Immunogenicity Phase) – locally advanced or metastatic PDAC

Part B (Safety and Immunogenicity Combination Phase) – resected or locally advanced PDAC

Part C (Efficacy Phase)- resected PDAC

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.